Clinical Trial

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effects of KarXT administration on the drug levels of midazolam, fexofenadine, and digoxin in healthy adult participants.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-23
notable Primary completion pushed: 2026-04-05 -> 2026-06-25 2026-06-12
minor Completion pushed: 2026-04-05 -> 2026-06-25 2026-06-12
Trial Details
NCT Number NCT07118215
Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Conditions Healthy Volunteers
Enrollment 62 participants
Start Date 2025-09-29
Primary Completion 2026-06-25 (estimated)
Study Completion 2026-06-25 (estimated)
Updated on ClinicalTrials.gov 2026-07-22